Scientific article
OA Policy
English

Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms

Published inCirculation, vol. 103, no. 4, p. 544-548
Publication date2001
Abstract

Inhaled nitric oxide (iNO) has been used to assess the vasodilator capacity of the pulmonary vascular bed in children with congenital heart disease and elevated pulmonary vascular resistance. Inhaled iloprost is a pulmonary vasodilator for the long-term treatment of pulmonary hypertension (PHT). Because these 2 vasodilators act through different pathways (release of cGMP or cAMP, respectively), we compared the pulmonary vasodilator capacity of each.

Keywords
  • Administration, Inhalation
  • Aerosols
  • Analysis of Variance
  • Child
  • Child, Preschool
  • Cyclic AMP/blood
  • Cyclic GMP/blood
  • Heart Defects, Congenital/complications
  • Hemodynamics/drug effects
  • Humans
  • Hypertension, Pulmonary/drug therapy/etiology/physiopathology
  • Iloprost/administration & dosage
  • Infant
  • Lung/blood supply/drug effects/physiopathology
  • Nitric Oxide/administration & dosage
  • Pulmonary Circulation/drug effects
  • Vascular Resistance/drug effects
  • Vasodilator Agents/administration & dosage
Citation (ISO format)
RIMENSBERGER, Peter et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. In: Circulation, 2001, vol. 103, n° 4, p. 544–548. doi: 10.1161/01.CIR.103.4.544
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Journal ISSN0009-7322
555views
418downloads

Technical informations

Creation11/03/2015 15:48:00
First validation11/03/2015 15:48:00
Update time15/03/2023 00:01:27
Status update15/03/2023 00:01:27
Last indexation31/10/2024 00:30:10
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack